Compare Amphastar Pharmaceuticals Inc (AMPH) vs First Trust NASDAQ Cybersecurity ETF (CIBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs First Trust NASDAQ Cybersecurity ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $26.22 (market cap $1.11B), while First Trust NASDAQ Cybersecurity ETF trades at $101.83 (market cap $17.34B). The key difference: First Trust NASDAQ Cybersecurity ETF is far larger — about 15.6× Amphastar Pharmaceuticals Inc's market cap, and Amphastar Pharmaceuticals Inc is more actively traded (390,201 versus 1,561,905). Which is the better fit depends on your goals — on Pluang, investors hold Amphastar Pharmaceuticals Inc for 17 Days and First Trust NASDAQ Cybersecurity ETF for 115 Days on average.
| AMPH | CIBR | |
|---|---|---|
Market Cap | $1.11B | $17.34B |
Volume | 390,201 | 1,561,905 |
Sector | Health | — |
52-Week High | $29.40 | $110.00 |
52-Week Low | $16.87 | $60.74 |
Typical Hold Time | 17 Days | 115 Days |
Enterprise Value | $1.51B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $26.15, up 0.81% today, with mixed technical signals showing a neutral overall trend. The company reported Q2 2026 earnings beat with $0.91 EPS versus $0.62 expected, though Q1 and Q4 2025 missed estimates. Revenue grew to $183.9M in Q2 2026, while net income margin stands at 10.76% with solid profitability metrics. Recent news highlights analyst downgrades and insider selling activity.
The stock faces headwinds from analyst skepticism with a 'Reduce' consensus rating and price target of $21.00 below current levels. While operational cash flow remains strong at $156M, regulatory challenges including an FDA warning letter and potential generic drug tariffs present significant risks. The valuation appears reasonable with P/E of 15.5, but earnings consistency remains a concern for investors.
CIBR trades at $103.90, up 3.49% today, but technical indicators signal a bearish trend with moving averages and ADX showing selling pressure. The ETF faces valuation concerns despite strong sector positioning in cybersecurity. Recent news highlights AI-driven security demand as a potential catalyst, though some analysts warn of stretched valuations among top holdings.
The cybersecurity ETF benefits from structural growth in AI security needs, but current price levels reflect premium valuations that may limit near-term upside. Key risks include concentration in expensive holdings and potential sector rotation away from tech. Institutional activity shows mixed signals with both position increases and decreases reported.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About First Trust NASDAQ Cybersecurity ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index includes securities of companies classified as cyber security companies. The fund is non-diversified.
Read more on CIBR →
